MedTrace Logo

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2026-05-11

Study results available
· View outcomes & findings →

Summary

The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.

Conditions

Interventions

DRUG

Orticumab

A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope

DRUG

Placebo

Placebo for orticumab, containing all components of formulation except the active ingredient

Sponsors & Collaborators

  • Abcentra

    lead INDUSTRY

Principal Investigators

  • Joel Neutel, MD · Orange County Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-11-11
Completion
2022-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04776629 on ClinicalTrials.gov